Pre-clinical studies have shown that pan-PI3K inhibitors, AKT inhibitors, or mTOR inhibitors, in combination with MEK inhibitors, may deliver promising tumor suppressive effects in KRAS or BRAF-mutant tumors; however, the associated toxicity may still limit clinical benefits [169,170,171,172]. Here, MAP2K7 is linked to neoplasm.